What is GenuIN Biotech?
GenuIN Biotech specializes in the development and provision of validated antibodies and associated research products. Leveraging advanced knockdown and knockout techniques, the company ensures the reliability and accuracy of its offerings, which include KD-validated monoclonal antibodies, lentiviral particles, cell lines, and a variety of reagents. GenuIN Biotech also provides bespoke services, such as custom monoclonal antibody development and rigorous antibody validation, catering to researchers and laboratories that require high-quality tools for gene silencing and protein analysis.
How much funding has GenuIN Biotech raised?
GenuIN Biotech has raised a total of $23K across 1 funding round:
Debt
$23K
Debt (2021): $23K with participation from PPP
What's next for GenuIN Biotech?
With the recent influx of substantial expansion capital, GenuIN Biotech is poised for significant strategic advancement. This funding is expected to fuel further research and development, enhance production capabilities, and potentially broaden its market reach. The company's focus on validated antibodies and custom services positions it to capitalize on the growing demand for reliable tools in life science research, gene editing, and drug discovery. Future growth will likely involve scaling operations to meet increasing demand and potentially exploring new therapeutic areas or diagnostic applications.
See full GenuIN Biotech company page
